(lp0
S'Why Paratek Pharmaceuticals Inc Is Soaring Motley Fool - Apr 4, 2017 Paratek has been on a quite a roll recently. Just last week, the company and its partner Allergan  announced data from two phase 3 trials regarding sarecycline, a hopeful treatment for severe acne.Paratek Pharma shares surge 30% after antibiotic study results - MarketWatchParatek Pharmaceuticals Inc.  Surged To A New High On Study Results - RTT News'
p1
aS'Paratek Pharmaceuticals: A Significantly Derisked Core Buy In Biotech Seeking Alpha - Apr 10, 2017 Shares of Paratek Pharmaceuticals  have soared 45% in the past three months on the heels of positive results from a pivotal trial involving its broad spectrum antibiotic omadacycline in the treatment of community-acquired bacterial&nbsp;...'
p2
aS'Paratek Pharmaceuticals Inc  Scores a Home Run with Sarecycline Phase 3 Smarter Analyst - Mar 27, 2017 Paratek Pharmaceuticals Inc  shares are rising 11% today after the biotech firm and its collaborator Allergan posted a successful Phase 3 data read-out for sarecycline in the indication of the treatment of moderate to severe acne ...Paratek Pharmaceuticals Inc.  Surged On Phase 3 Study Results - RTT NewsPARATEK PHARMACEUTICALS, INC.  Files An 8-K Regulation FD Disclosure - Market Exclusive'
p3
aS'Special Situation Case Study - Paratek Pharmaceuticals, Inc. Seeking Alpha - Jan 17, 2017 For this purpose, we propose Paratek Pharmaceuticals, Inc.  because it is timely, is outside the realm of the typical special situation investments so commonly covered (e.Paratek Announces Completion of Enrollment in Omadacycline Phase 3 Community ... - GlobeNewswire '
p4
aS'Paratek Pharmaceuticals Inc  Given Positive Rating at Robert W. Baird Sports Perspectives - 3 hours ago Paratek Pharmaceuticals Inc logo Robert W. Baird reiterated their positive rating on shares of Paratek Pharmaceuticals Inc  in a research report released on Monday morning. Robert W. Baird currently has a $40.00 price target on the&nbsp;...Paratek Pharmaceuticals Inc  Rating Reiterated by Robert W. Baird - BBNSThe Paratek Pharmaceuticals Inc  Sees Large Increase in Short Interest - Petro Global News 24'
p5
aS'Checking on Shares of Paratek Pharmaceuticals, Inc.  The Standard - 19 hours ago Checking the Value Composite score for Paratek Pharmaceuticals, Inc. , we see that the company has a rank of 98.'
p6
aS'Paratek: CABP Read-Out Likely Positive Seeking Alpha - Feb 8, 2017 This study, which is designed to assess the efficacy and safety of intravenous  to once-daily oral omadacycline compared with moxifloxacin in subjects with CABP, enrolled its first patient in November 2015.Paratek Successfully Tackles Patient Challenges in Phase 3 Trial - Clinical Leader'
p7
aS'Paratek Pharmaceuticals Inc.  Breaks into New 52-Week High on March 31 ... Equities.com - Mar 31, 2017 Shares of Paratek Pharmaceuticals Inc.  broke into a new 52-week high yesterday, hitting a peak of $19.40. Shares closed at $19.25 after opening at $18.85 for a move of 2.39%.'
p8
aS'Paratek Pharmaceuticals Inc.  Breaks into New 52-Week High on April 04 ... Equities.com - Apr 4, 2017 Shares of Paratek Pharmaceuticals Inc.  broke into a new 52-week high yesterday, hitting a peak of $25.00. Shares closed at $22.85 after opening at $24.40 for a move of 22.85%.'
p9
aS'Paratek Pharmaceuticals Inc  Given Outperform Rating at Robert W. Baird The Cerbat Gem - Apr 10, 2017 Paratek Pharmaceuticals Inc logo Robert W. Baird restated their outperform rating on shares of Paratek Pharmaceuticals Inc  in a research note released on Tuesday. The brokerage currently has a $40.00 target price on the specialty&nbsp;...Paratek Pharmaceuticals Inc  Given New $56.00 Price Target at BTIG Research - Sports PerspectivesWhy Investors remained confident on Paratek Pharmaceuticals, Inc. (PRTK ... - StockNewsJournal'
p10
a.